Kisqali® Improves Outcomes for Premenopausal Women with HR+/HER2- Advanced Breast Cancer

(November 14, 2017)

Premenopausal breast cancer is a biologically distinct and more aggressive disease than postmenopausal breast cancer and is the leading cause of cancer death in women 20-59 years old.1,2 ,3 Historically there younger women were treated the same as their... Continue Reading


Nerlynx Modestly Improves Survival of HER 2-Positive Early Stage Breast Cancer

(November 1, 2017)

Positive results from the clinical trial evaluating neratinib for the extended adjuvant treatment of early stage HER2-positive breast cancer following trastuzumab-based therapy (ExteNET trial) were presented at the European Society of Medical Oncology... Continue Reading


Verzenio Demonstrates Superior Progression-Free Survival in Advanced Breast Cancer

(October 30, 2017)

Recently released clinical trial results from the Phase 3 MONARCH 2 study showed that Verzenio (abemaciclib), a cyclin-dependent kinase (CDK) 4 & 6 inhibitor, when administered in combination with fulvestrant, significantly improves the time to cancer... Continue Reading


Radius Health Receives FDA Fast Track Designation for Elacestrant

(October 26, 2017)

The U.S. Food and Drug Administration (FDA) has granted Fast Track designation for elacestrant, an investigational oral selective estrogen receptor down-regulator/degrader (SERD) as a treatment of women with ER+ and HER2- advanced or metastatic breast... Continue Reading


Immunotherapy Active Against Triple-Negative Breast Cancer

(October 12, 2017)

October is breast cancer awareness month and patients with triple-negative breast cancer (TNBC) should be aware that data from two clinical trials provide additional evidence that they may derive benefit from checkpoint inhibitor therapy.1-4 About Triple... Continue Reading


LynparzaTM Slows Spread of Inherited Breast Cancer Caused By BRCA Mutations

(October 10, 2017)

LynparzaTM (olaparib), a new drug treatment for women with advanced ovarian cancer associated with defective BRCA genes also appears to slowe the progression of breast cancer caused in part by mutations in the BRCA gene.  BRCA is an inherited condition... Continue Reading


FDA approves new treatment for certain advanced or metastatic breast cancers

(October 5, 2017)

The U.S. Food and Drug Administration today approved Verzenio (abemaciclib) to treat adult patients who have hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer that has progressed... Continue Reading


Annual Mammography Starting at Age 40 Prevents the Most Cancer Deaths

(September 13, 2017)

When to initiate screening for breast cancer, how often to screen, and how long to screen are questions that continue to spark emotional debates. A new study compares the number of deaths that might be prevented as a result of three of the most widely... Continue Reading


FDA Grants Breakthrough Therapy Designation to DS-8201 for HER2-Positive Metastatic Breast Cancer

(August 30, 2017)

The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to DS-8201, an investigational HER2-targeting antibody drug conjugate (ADC), for the treatment of patients with HER2-positive, locally advanced or metastatic breast... Continue Reading


Nipple-Sparing Mastectomy Has Low Rate of Breast Cancer Recurrence

(August 1, 2017)

Investigators say most women with breast cancer are eligible for this type of mastectomy, which leaves the natural nipple in place Women with breast cancer who undergo nipple-sparing mastectomy (NSM) have a low rate of the cancer returning within the... Continue Reading


Latest Breast Cancer News By Stage


Carcinoma In Situ Breast cancer

ASCO Publishes Breast Cancer Survivorship Guidelines

(January 25, 2016)

The American Society of Clinical Oncology (ASCO), in collaboration with the American Cancer Society (ACS), have released updated guidelines regarding follow-up care for breast cancer survivors. The updated guidelines were recently published in the Journal... Continue Reading


Quality of Life Helps Determine Type of Hormone Treatment in Early Breast Cancer

(January 20, 2016)

Quality of life issues and different side effects caused by treatment may help determine which type of hormone therapy is most appropriate for postmenopausal women with ductal carcinoma in situ, particularly among women 60 years of age or older. These... Continue Reading


Radiation Essential to Controlling Long-Term Recurrence in Women With Early Form of Breast Cancer

(October 1, 2015)

Doctors have reported that rates of breast cancer recurrences continue to increase, even after 12 years, among patients with ductal carcinoma in situ (DCIS) who do not receive radiation therapy as part of their treatment regimen. These results were recently... Continue Reading


Biomarker May Help Improve Treatment of Triple-Negative Breast Cancer

(September 8, 2015)

Researchers have found a biomarker that appears active in the growth and spread of triple-negative breast cancer. Known as interleukin-13 receptor alpha 2 (IL13Ralpha2), the biomarker may help doctors identify patients at high risk of disease spread and... Continue Reading


Women with Early Breast Cancer Have Fewer Side Effects with Shorter Courses of Radiation

(September 1, 2015)

Women with early breast cancer have fewer side effects when they’re treated with shorter courses of radiation at higher doses than with conventional radiation to the whole breast. These findings were reported in JAMA Oncology.[1] Treatment with shorter... Continue Reading


More Carcinoma In Situ Breast cancer

Inflammatory Breast Cancer

ASCO Publishes Breast Cancer Survivorship Guidelines

(January 25, 2016)

The American Society of Clinical Oncology (ASCO), in collaboration with the American Cancer Society (ACS), have released updated guidelines regarding follow-up care for breast cancer survivors. The updated guidelines were recently published in the Journal... Continue Reading


Breast Cancer Research: Have We Made Progress?

(January 27, 2015)

Published results from research studies in breast cancer in the last year represent several practice changing milestones. CancerConnect News coverage of advances in the management of breast cancer included the following key developments: 2014: Have we... Continue Reading


Walk or Run Your Way to a Reduced Risk of Breast Cancer

(September 24, 2014)

Want to reduce your risk of breast cancer? Lace up those shoes and get moving—because exercise has a significant impact. There is a growing body of evidence to indicate that exercise is crucial to reducing the risk of cancer. Now a new study has put... Continue Reading


Risk of Breast Cancer Recurrence Doesn’t Increase with TNF Inhibitor Use

(August 28, 2014)

According to the results of a recently published study from Swedish investigators treatment with tumor necrosis factor inhibitors (TNF) does not appear to increase the rate of breast cancer recurrence among patients with rheumatoid arthritis (RA).  The... Continue Reading


Ask the Expert: Making Informed Decisions about Breast Reconstruction

(June 18, 2014)

July 16, 2014 at 6:30pm EST CancerConnect live Web Chat with an Expert series presents:  “Making Informed Decisions about Breast Reconstruction.”  On July 16, 2014 at 6:30pm EST you will have the opportunity to engage with a breast cancer expert... Continue Reading


More Inflammatory Breast Cancer

Metastatic Breast Cancer

FDA approves new treatment for certain advanced or metastatic breast cancers

(October 5, 2017)

The U.S. Food and Drug Administration today approved Verzenio (abemaciclib) to treat adult patients who have hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer that has progressed... Continue Reading


FDA Grants Breakthrough Therapy Designation to DS-8201 for HER2-Positive Metastatic Breast Cancer

(August 30, 2017)

The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to DS-8201, an investigational HER2-targeting antibody drug conjugate (ADC), for the treatment of patients with HER2-positive, locally advanced or metastatic breast... Continue Reading


Kisqali® Receives FDA Approval as First Line Treatment for HR+/HER2- Metastatic Breast Cancer

(March 16, 2017)

The US Food and Drug Administration (FDA) has approved the investigational drug Kisqali® (ribociclib, LEE011) for first line treatment of hormone receptor + HER 2- metastatic breast cancer because when combined with Femera (letrozole) the combination... Continue Reading


Keytruda®/Halaven® Combo May Be Effective in Advanced Triple-Negative Breast Cancer

(January 9, 2017)

The investigative treatment combination including Keytruda® (pembrolizumab) plus Halaven® (eribulin) could provide a potential therapeutic option for patients with advanced triple-negative breast cancer (TNBC) whose disease has advanced following prior... Continue Reading


Ribociclib Offers ‘Paradigm Shift’ in Advanced Breast Cancer

(October 26, 2016)

The investigational drug ribociclib (formerly LEE011) when combined with Femera (letrozole) for the initial treatment of postmenopausal women with hormone-receptor positive (HR+) metastatic breast cancer leads to improved survival without cancer recurrence. The... Continue Reading


More Metastatic Breast Cancer

Recurrent Breast Cancer

Tecentriq™ Plus Abraxane® Effective Combo in Difficult to Treat Breast Cancer

(June 30, 2016)

The combination of the immune stimulating agent Tecentriq™ (atezolizumab), plus the chemotherapy agent Abraxane® (nab-paclitaxel) is effective in providing anti-cancer responses among patients with advanced triple-negative breast cancer (TNBC). These... Continue Reading


Directly Involving Patients Drives Participation in Metastatic Breast Cancer Study

(June 22, 2016)

A clinical study to accelerate research in metastatic breast cancer has rapidly enrolled participants through direct collaboration with patients. These results were recently presented at the 2016 annual meeting of the American Society of Clinical Oncology... Continue Reading


ASCO Publishes Breast Cancer Survivorship Guidelines

(January 25, 2016)

The American Society of Clinical Oncology (ASCO), in collaboration with the American Cancer Society (ACS), have released updated guidelines regarding follow-up care for breast cancer survivors. The updated guidelines were recently published in the Journal... Continue Reading


Blood Test May Predict Cancer Recurrences Earlier than Standard Methods

(October 26, 2015)

A blood test that can detect circulating DNA from cancer cells appears to accurately predict the risk of a breast cancer recurrence 8 months earlier than standard detection methods among women with high-risk breast cancer. However, further study is necessary... Continue Reading


Abemaciclib Receives FDA Breakthrough Therapy Designation in Advanced Breast Cancer

(October 9, 2015)

The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to abemaciclib, a cyclin-dependent kinase (CDK) 4 and 6 inhibitor, for patients with refractory hormone-receptor-positive (HR+) advanced or metastatic breast cancer. According... Continue Reading


More Recurrent Breast Cancer

Screening/Prevention Breast Cancer

It’s in the Genes: Top 5 Things to Know about Genetic Testing

(July 8, 2016)

Advances in genetic testing are offering women more information than ever before about their genetic makeup and are providing opportunities for empowered decision-making related to a wide range of health issues. In this recurring column, experts provide... Continue Reading


Counsyl Announces Major Oncology Expansion to Advance Genetic Screening for Cancer Risk

(May 25, 2016)

Counsyl launches oncology business unit, an expanded test to assess risk for inherited forms of cancer, and tools to improve genetic screening rates across the healthcare system Counsyl, a DNA testing and genetic counseling service, today announced its... Continue Reading


3D Mammography Proves More Accurate in Breast Cancer Detection

(March 31, 2016)

Longer follow-up evaluating digital breast tomosynthesis (DBT), also referred to as 3D mammography, demonstrates its continued effectiveness compared to standard digital mammography (DM) when screening for breast cancer. These results were recently published... Continue Reading


ASCO Publishes Breast Cancer Survivorship Guidelines

(January 25, 2016)

The American Society of Clinical Oncology (ASCO), in collaboration with the American Cancer Society (ACS), have released updated guidelines regarding follow-up care for breast cancer survivors. The updated guidelines were recently published in the Journal... Continue Reading


Blood Test May Predict Cancer Recurrences Earlier than Standard Methods

(October 26, 2015)

A blood test that can detect circulating DNA from cancer cells appears to accurately predict the risk of a breast cancer recurrence 8 months earlier than standard detection methods among women with high-risk breast cancer. However, further study is necessary... Continue Reading


More Screening/Prevention Breast Cancer

Stage I Node Negative Breast Cancer

MammaPrint Might Help Identify Breast Cancer Patients Who Could Safely Opt Out of Chemo

(September 7, 2016)

MammaPrint, a 70-gene signature test, might help healthcare providers and patients determine whether they will derive a benefit from chemotherapy, or if they could safely choose to not receive chemotherapy for early-stage breast cancer. These results... Continue Reading


Neratinib Improves Cancer-Free Survival in Early Breast Cancer

(July 27, 2016)

The targeted agent neratinib (PB272), which is still in clinical trials, demonstrated an improvement in cancer-free survival when used after Herceptin® (trastuzumab) in early-stage, HER2-positive breast cancer. Approximately 20-30% of breast cancer is... Continue Reading


Treatment with Aromatase Inhibitors for 10 Years Improves Cancer-Free Survival in Breast Cancer

(June 7, 2016)

Among postmenopausal women with hormone-positive, early breast cancer, treatment with aromatase inhibitors (AIs) for 10 years significantly improves cancer-free survival, compared to the 5-year standard length of AI treatment.  However, quality of life... Continue Reading


Some Premenopausal Women Benefit from Exemestane Compared to Tamoxifen

(April 28, 2016)

Among premenopausal women with hormone-positive, early breast cancer who are considered to have a high risk of a cancer recurrence, the use of Aromasin® (exemestane) versus tamoxifen improves cancer-free survival at 5 years. These results were recently... Continue Reading


Dose-Dense Chemotherapy for Premenopausal Breast Cancer Improves Survival

(March 28, 2016)

Premenopausal women who have been diagnosed with breast cancer have improved survival if their chemotherapy doses are delivered every two weeks, compared to every three weeks. These results were recently presented at the 2016 European Breast Cancer Conference... Continue Reading


More Stage I Node Negative Breast Cancer

Stages II-III Breast Cancer

Kisqali® Receives FDA Approval as First Line Treatment for HR+/HER2- Metastatic Breast Cancer

(March 16, 2017)

The US Food and Drug Administration (FDA) has approved the investigational drug Kisqali® (ribociclib, LEE011) for first line treatment of hormone receptor + HER 2- metastatic breast cancer because when combined with Femera (letrozole) the combination... Continue Reading


Neratinib Improves Cancer-Free Survival in Early Breast Cancer

(July 27, 2016)

The targeted agent neratinib (PB272), which is still in clinical trials, demonstrated an improvement in cancer-free survival when used after Herceptin® (trastuzumab) in early-stage, HER2-positive breast cancer. Approximately 20-30% of breast cancer is... Continue Reading


Some Premenopausal Women Benefit from Exemestane Compared to Tamoxifen

(April 28, 2016)

Among premenopausal women with hormone-positive, early breast cancer who are considered to have a high risk of a cancer recurrence, the use of Aromasin® (exemestane) versus tamoxifen improves cancer-free survival at 5 years. These results were recently... Continue Reading


Dose-Dense Chemotherapy for Premenopausal Breast Cancer Improves Survival

(March 28, 2016)

Premenopausal women who have been diagnosed with breast cancer have improved survival if their chemotherapy doses are delivered every two weeks, compared to every three weeks. These results were recently presented at the 2016 European Breast Cancer Conference... Continue Reading


ASCO Publishes Breast Cancer Survivorship Guidelines

(January 25, 2016)

The American Society of Clinical Oncology (ASCO), in collaboration with the American Cancer Society (ACS), have released updated guidelines regarding follow-up care for breast cancer survivors. The updated guidelines were recently published in the Journal... Continue Reading


More Stages II-III Breast Cancer

Supportive Care Breast Cancer

ASCO Publishes Breast Cancer Survivorship Guidelines

(January 25, 2016)

The American Society of Clinical Oncology (ASCO), in collaboration with the American Cancer Society (ACS), have released updated guidelines regarding follow-up care for breast cancer survivors. The updated guidelines were recently published in the Journal... Continue Reading


Breast Cancer Research: Have We Made Progress?

(January 27, 2015)

Published results from research studies in breast cancer in the last year represent several practice changing milestones. CancerConnect News coverage of advances in the management of breast cancer included the following key developments: 2014: Have we... Continue Reading


Risk of Breast Cancer Recurrence Doesn’t Increase with TNF Inhibitor Use

(August 28, 2014)

According to the results of a recently published study from Swedish investigators treatment with tumor necrosis factor inhibitors (TNF) does not appear to increase the rate of breast cancer recurrence among patients with rheumatoid arthritis (RA).  The... Continue Reading


Ask the Expert: Making Informed Decisions about Breast Reconstruction

(June 18, 2014)

July 16, 2014 at 6:30pm EST CancerConnect live Web Chat with an Expert series presents:  “Making Informed Decisions about Breast Reconstruction.”  On July 16, 2014 at 6:30pm EST you will have the opportunity to engage with a breast cancer expert... Continue Reading


Ask the Expert: Breast Cancer, Diet and Exercise

(May 19, 2014)

CancerConnect recently partnered with Dana-Farber to provide you with the opportunity to engage with a breast cancer expert, Jennifer A. Ligibel, MD, of the Susan F. Smith Center for Women’s Cancers at Dana-Farber. On May 7 and 8, 2014, Dr. Ligibel... Continue Reading


More Supportive Care Breast Cancer